← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS › Macrolides
miocamycin
J01FA11
Forms & Strengths
- Oral tablets 300 mg
- Oral suspension 200 mg/5 mL
Adult Dosing
- 600 mg to 1200 mg daily divided in 2 to 3 doses
- Severe infections: Up to 1800 mg daily in divided doses
Pediatric Dosing
- Children > 1 month: 30 to 50 mg/kg/day divided in 2 to 3 doses
- Maximum daily dose should not exceed adult dosing parameters based on weight
Indications
- Upper and lower respiratory tract infections caused by susceptible organisms
- Skin and soft tissue infections
- Ear, nose, and throat infections
Mechanism of Action
- Macrolide antibiotic inhibiting bacterial protein synthesis
- Binds reversibly to the 50S ribosomal subunit
- Inhibits transpeptidation and translocation steps
Contraindications
- Known hypersensitivity to miocamycin or other macrolide antibiotics
- Severe hepatic impairment
- Concurrent administration with ergotamine or dihydroergotamine
Adverse Reactions
- Gastrointestinal disturbances (nausea, vomiting, abdominal pain, diarrhea)
- Transient elevation of liver transaminases
- Allergic skin reactions (rash, urticaria)
- Dizziness or headache
Drug Interactions
- Inhibits CYP3A4, potentially increasing serum levels of carbamazepine, cyclosporine, and digoxin
- Increases risk of ergotism when co-administered with ergot derivatives
- May enhance the anticoagulant effect of oral anticoagulants like warfarin
Curated Content: Needs Vetting Before Put to Clinical Use